NKTR vs UPST · rev $21.0M vs P/E 74, rev $672.9M
Nektar Therapeutics (NKTR) versus Upstart Holdings Inc (UPST) — a side-by-side from cached financials, not a winner call.
Nektar Therapeutics (NKTR) is a biotechnology company listed on US.
Upstart Holdings Inc (UPST) is a credit services company listed on NASDAQ.
Latest reported NKTR revenue for 2026-06-30 was $21.0M. Net income was -$85.5M. Revenue was up 93.3% from 2026-03-31 to 2026-06-30. NKTR currently screens at market cap $307.2M.
Latest reported UPST revenue for 2026-06-30 was $672.9M. Net income was $9.9M. UPST currently screens at market cap $2.92B and trailing P/E 74.3.
NKTR currently screens at market cap $307.2M. UPST currently screens at market cap $2.92B and trailing P/E 74.3.
Not investment advice. Open the NKTR and UPST stock pages for the full models.
Not investment advice.